ERK 1/2 Pathways: Discoveries in Disease Causation and Developments in Their Treatment

This study delves into recent research on ERK1/2 signaling pathways, exploring their critical role in cellular processes such as proliferation, differentiation, migration, and apoptosis. Dysregulation of these pathways contributes to various human diseases, including cancers, autoimmune disorders, and neurodegenerative conditions. The study highlights the potential therapeutic benefits of targeting ERK1/2 through inhibitors, which demonstrate efficacy in treating autoimmune and inflammatory diseases, as well as cancer. However, issues like drug resistance, off-target effects, and unintended consequences of systemic MEK/ERK inhibition present challenges. Tumor progression locus 2 (TPL2) is an important regulator of immune responses that conveys inflammatory signals to downstream effectors, Targeting upstream regulators like TPL2 or employing combinatorial therapies such as inhibition of Akt may offer more precise treatment approaches. The study also explores emerging treatments, including kinase inhibitors from extremophilic microorganisms, which offer new perspectives on drug development. Ultimately, a comprehensive understanding of ERK1/2's potential targets is crucial to developing effective therapies for a range of diseases, promising significant advances in public health.